In addition, in vitro studies have demonstrated that Disitamab Vedotin exhibits antibody-dependent cell-mediated cytotoxicity (ADCC) effects against HER2-overexpressing cancer cells, thereby exerting a tumor-inhibitory effect [10]. Here, ERBB2 is linked to cancer.